CL2012003643A1 - Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. - Google Patents

Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Info

Publication number: CL2012003643A1
Authority: CL; Chile
Prior art keywords: compound; dyslipidemia; glucagon; hypertension; treat
Prior art date: 2010-06-23

Application number

CL2012003643A

Other languages

English (en)

Inventor

Marie Skovgaard

Ditte Riber

Eddi Meier

Jens Rosengren Daugaard

Original Assignee

Zealand Pharma As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2012-12-21

Publication date

2013-08-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-21 Application filed by Zealand Pharma As filed Critical Zealand Pharma As

2013-08-02 Publication of CL2012003643A1 publication Critical patent/CL2012003643A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
208000032928 Dyslipidaemia Diseases 0.000 title 1
102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
206010020772 Hypertension Diseases 0.000 title 1
208000017170 Lipid metabolism disease Diseases 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2012003643A 2010-06-23 2012-12-21 Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. CL2012003643A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA201000550		2010-06-23
US35862310P	2010-06-25	2010-06-25

Publications (1)

Publication Number	Publication Date
CL2012003643A1 true CL2012003643A1 (es)	2013-08-02

Family

ID=44630045

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2012003643A CL2012003643A1 (es)	2010-06-23	2012-12-21	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.

Country Status (23)

Country	Link
US (2)	US9403894B2 (es)
EP (1)	EP2585481B1 (es)
JP (1)	JP5937582B2 (es)
KR (1)	KR20130086339A (es)
CN (1)	CN103038250A (es)
AP (1)	AP3286A (es)
AR (1)	AR081975A1 (es)
AU (1)	AU2011269427A1 (es)
BR (1)	BR112012033227A2 (es)
CA (1)	CA2802889A1 (es)
CL (1)	CL2012003643A1 (es)
CO (1)	CO6660484A2 (es)
EA (1)	EA201291233A1 (es)
EC (1)	ECSP12012351A (es)
MX (1)	MX2012014774A (es)
NZ (1)	NZ604033A (es)
PE (1)	PE20130326A1 (es)
PH (1)	PH12012502461A1 (es)
SG (1)	SG186276A1 (es)
TN (1)	TN2012000567A1 (es)
TW (1)	TW201202265A (es)
UY (1)	UY33462A (es)
WO (1)	WO2011160630A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2006242998B2 (en)	2005-05-04	2012-03-22	Zealand Pharma A/S	Glucagon-like-peptide-2 (GLP-2) analogues
UA102506C2 (ru)	2006-11-08	2013-07-25	Зиланд Фарма А/С	Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
WO2010070253A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010070255A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
AU2008365556A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
WO2010070251A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
CN104961822A (zh)	2009-07-13	2015-10-07	西兰制药公司	酰化胰高血糖素类似物
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
AU2011269430A1 (en)	2010-06-24	2013-01-10	Zealand Pharma A/S	Glucagon analogues
PH12013501495A1 (en) *	2011-01-20	2013-09-16	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
EP2758426B1 (en)	2011-09-23	2019-08-07	Novo Nordisk A/S	Novel glucagon analogues
BR112014015681A2 (pt) *	2011-12-23	2019-09-24	Boehringer Ingelheim Int	análogos de glucagon
EA028665B1 (ru)	2012-05-03	2017-12-29	Зилэнд Фарма А/С	Соединения - двойные агонисты gip-glp-1 и способы
EA028929B1 (ru) *	2012-05-03	2018-01-31	Зилэнд Фарма А/С	Аналоги глюкагоноподобного пептида-2 (glp-2)
MX2014015423A (es)	2012-06-14	2015-04-09	Sanofi Sa	Analogos de peptido de exedina-4.
JP6534927B2 (ja)	2012-07-23	2019-06-26	ジーランドファーマアクティーゼルスカブ	グルカゴン類似体
TWI608013B (zh) *	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9546205B2 (en)	2012-09-17	2017-01-17	Imperial Innovations Limited	Peptide analogues of glucagon and GLP1
GB2505941A (en) *	2012-09-17	2014-03-19	Imp Innovations Ltd	Peptide analogues of glucagon for the treatment of obesity and diabetes
UA116217C2 (uk) *	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SI2934568T1 (en)	2012-12-21	2018-03-30	Sanofi	Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
ES2623979T3 (es)	2013-03-21	2017-07-12	Sanofi-Aventis Deutschland Gmbh	Síntesis de productos peptídicos que contienen hidantoína
CN105102427B (zh)	2013-03-21	2018-09-07	赛诺菲-安万特德国有限公司	含有环状酰亚胺的肽产物的合成
AR095986A1 (es)	2013-04-03	2015-11-25	Sanofi Sa	Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
WO2014170496A1 (en)	2013-04-18	2014-10-23	Novo Nordisk A/S	Stable, protracted glp-1/glucagon receptor co-agonists for medical use
CN119119233A (zh)	2013-10-17	2024-12-13	西兰制药公司	酰化胰高血糖素类似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
KR102310392B1 (ko)	2013-11-06	2021-10-13	질랜드 파마 에이/에스	글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
CA2929459C (en)	2013-11-06	2022-05-03	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
TW201609800A (zh)	2013-12-13	2016-03-16	賽諾菲公司	做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
TW201609795A (zh)	2013-12-13	2016-03-16	賽諾菲公司	作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086729A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/gip receptor agonists
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
WO2015185640A1 (en)	2014-06-04	2015-12-10	Novo Nordisk A/S	Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
WO2016133863A1 (en)	2015-02-17	2016-08-25	Eli Lilly And Company	Nasal powder formulation for treatment of hypoglycemia
KR20170126504A (ko)	2015-03-18	2017-11-17	질랜드 파마 에이/에스	아밀린 유사체
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
AU2016247499B2 (en)	2015-04-16	2020-09-03	Zealand Pharma A/S	Acylated glucagon analogue
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN109562144A (zh)	2016-06-09	2019-04-02	阿米德生物有限责任公司	胰高血糖素类似物及其使用方法
LT3494120T (lt)	2016-08-05	2021-05-25	Boehringer Ingelheim International Gmbh	Oksadiazolopiridino dariniai, skirti naudoti kaip grelino o-aciltransferazės (goat) inhibitoriai
AR109514A1 (es)	2016-09-09	2018-12-19	Zealand Pharma As	Análogos de amilina
KR101887577B1 (ko) *	2016-10-19	2018-09-10	(주)케어젠	항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AR110299A1 (es)	2016-12-02	2019-03-13	Sanofi Sa	Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
EP3881861B1 (en)	2017-06-16	2024-07-31	Zealand Pharma A/S	Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
BR112020003319A2 (pt) *	2017-08-16	2020-08-25	Dong-A St Co., Ltd.	análogo de peptídeo de oxintomodulina acilada
WO2019149657A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
EA202091803A1 (ru)	2018-02-02	2020-12-16	Бёрингер Ингельхайм Интернациональ Гмбх	Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
US11136337B2 (en)	2018-02-02	2021-10-05	Boehringer Ingelheim International Gmbh	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors
EA202091804A1 (ru)	2018-02-02	2020-12-24	Бёрингер Ингельхайм Интернациональ Гмбх	Гетероциклил-замещенные оксадиазолопиридиновые производные для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
WO2019197466A1 (en) *	2018-04-10	2019-10-17	Sanofi-Aventis Deutschland Gmbh	Method for cleavage of solid phase-bound peptides from the solid phase
AU2019250362B2 (en)	2018-04-10	2025-11-06	Sanofi-Aventis Deutschland Gmbh	Lixisenatide synthesis with capping
BR112021011595A2 (pt)	2018-12-21	2021-11-30	Jiangsu Hengrui Medicine Co	Proteína biespecífica
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
CA3147770A1 (en) *	2019-08-13	2021-02-18	Jae Ha Ryu	Exenatide analog and use thereof
MX2022005661A (es)	2019-11-11	2022-09-07	Boehringer Ingelheim Int	Agonistas del receptor npy2.
HUE066997T2 (hu)	2020-05-22	2024-09-28	Boehringer Ingelheim Int	Eljárás alkil-7-amino-5-metil-[1,2,5]oxidiazol[3,4-B]piridin-karboxilát elõállítására
CN115916789B (zh)	2020-05-22	2025-06-27	勃林格殷格翰国际有限公司	制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
CN113278060B (zh) *	2020-05-29	2022-03-25	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
AU2021322137A1 (en)	2020-08-07	2023-01-19	Boehringer Ingelheim International Gmbh	Soluble NPY2 receptor agonists
WO2024165571A2 (en)	2023-02-06	2024-08-15	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025125576A2 (en)	2023-12-15	2025-06-19	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025133348A1 (en)	2023-12-22	2025-06-26	E-Therapeutics Plc	Inhibitors of expression and/or function
WO2025196502A1 (en)	2024-03-20	2025-09-25	North Carolina Agricultural & Technical State University	Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en)	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
EP1826216A1 (en)	1996-08-30	2007-08-29	Novo Nordisk A/S	Glp-1 derivatives
EP0929567B1 (en)	1996-09-09	2005-03-02	Zealand Pharma A/S	Solid-phase peptide synthesis
IL128828A0 (en)	1996-09-09	2000-01-31	Zealand Pharmaceuticals As	Peptide prodrugs containing an alpha-hydroxy acid linker
AU757748B2 (en)	1997-11-14	2003-03-06	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
CA2321026A1 (en)	1998-03-09	1999-09-16	Zealand Pharmaceuticals A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
CZ295889B6 (cs)	1998-12-07	2005-11-16	Societe De Conseils De Recherches Et D'application	Analogy GLP-1, mající arginin na pozicích 26 a 34, jejich použití a farmaceutické prostředky je obsahující
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
DE60040333D1 (de)	1999-03-17	2008-11-06	Novo Nordisk As	Verfahren zur acylierung von peptiden und proteinen
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AU2002346491A1 (en)	2001-12-19	2003-07-09	Eli Lilly And Company	Crystalline compositions for controlling blood glucose
HUP0700126A2 (en)	2001-12-20	2007-06-28	Lilly Co Eli	Insulin molecule having protracted time action
GB0300571D0 (en)	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004096854A2 (en)	2003-04-29	2004-11-11	Eli Lilly And Company	Insulin analogs having protracted time action
ATE553124T1 (de)	2005-06-13	2012-04-15	Imp Innovations Ltd	Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
US20090202497A1 (en)	2005-08-23	2009-08-13	The General Hospital Corporation	Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2628241C (en)	2005-11-07	2016-02-02	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting physiological solubility and stability
WO2007081824A2 (en)	2006-01-06	2007-07-19	Case Western Reserve University	Fibrillation resistant proteins
EP2471810A1 (en)	2006-02-22	2012-07-04	Merck Sharp & Dohme Corporation	Oxyntomodulin derivatives
MY157757A (en)	2006-07-18	2016-07-15	Sanofi Aventis	Antagonist antibody against epha2 for the treatment of cancer
ES2554773T3 (es)	2006-10-04	2015-12-23	Case Western Reserve University	Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh)	2006-12-13	2014-03-01	Imp Innovations Ltd	新穎化合物及其等對進食行為影響
GEP20135944B (en)	2007-02-15	2013-10-25	Indiana Unversity Research And Tech Corporation	Glucagon/glp-1 receptor co-agonists
EP2025684A1 (en)	2007-08-15	2009-02-18	Zealand Pharma A/S	Glucagon analogues
ATE520714T1 (de)	2007-06-15	2011-09-15	Zealand Pharma As	Glucagonanaloga
EP2930182A1 (en)	2007-11-20	2015-10-14	Ambrx, Inc.	Modified insulin polypeptides and their uses
WO2009087081A2 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue insulinderivate mit extrem verzögertem zeit-/wirkungsprofil
WO2009087082A2 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
DE102008003568A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de)	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en)	2008-04-14	2015-03-31	Case Western Reserve University	Meal-time insulin analogues of enhanced stability
NZ588857A (en)	2008-04-22	2012-07-27	Univ Case Western Reserve	Isoform-specific insulin analogue for control blood sugar levels
TWI451876B (zh)	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
EP2307037A4 (en)	2008-06-17	2011-08-03	Univ Indiana Res & Tech Corp	GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
TWI474832B (zh)	2008-06-17	2015-03-01	Univ Indiana Res & Tech Corp	胰高血糖素／ｇｌｐ-１受體共同激動劑
PL219335B1 (pl)	2008-07-04	2015-04-30	Inst Biotechnologii I Antybiotyków	Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
ES2552636T3 (es)	2008-07-31	2015-12-01	Case Western Reserve University	Insulina estabilizada por halógenos
WO2010070253A1 (en)	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010070255A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
WO2010070251A1 (en) *	2008-12-15	2010-06-24	Zealand Pharma A/S	Glucagon analogues
AU2008365556A1 (en)	2008-12-15	2011-07-21	Zealand Pharma A/S	Glucagon analogues
JP5755566B2 (ja)	2008-12-19	2015-07-29	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	アミド系インスリンプロドラッグ
JP5789515B2 (ja)	2008-12-19	2015-10-07	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	インスリン類似体
CN101519446A (zh)	2009-03-31	2009-09-02	上海一就生物医药有限公司	一种重组人胰岛素及其类似物的制备方法
CN104961822A (zh)	2009-07-13	2015-10-07	西兰制药公司	酰化胰高血糖素类似物
EA026384B1 (ru) *	2010-01-20	2017-04-28	Зилэнд Фарма А/С	Лечение заболеваний сердца
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
AU2011269430A1 (en)	2010-06-24	2013-01-10	Zealand Pharma A/S	Glucagon analogues
PH12013501495A1 (en)	2011-01-20	2013-09-16	Zealand Pharma As	Combination of acylated glucagon analogues with insulin analogues
BR112014015681A2 (pt)	2011-12-23	2019-09-24	Boehringer Ingelheim Int	análogos de glucagon
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
CN119119233A (zh)	2013-10-17	2024-12-13	西兰制药公司	酰化胰高血糖素类似物

2011
- 2011-06-22 UY UY0001033462A patent/UY33462A/es not_active Application Discontinuation
- 2011-06-22 AR ARP110102166A patent/AR081975A1/es unknown
- 2011-06-23 CA CA2802889A patent/CA2802889A1/en not_active Abandoned
- 2011-06-23 US US13/702,841 patent/US9403894B2/en not_active Expired - Fee Related
- 2011-06-23 EP EP11741513.3A patent/EP2585481B1/en active Active
- 2011-06-23 TW TW100122081A patent/TW201202265A/zh unknown
- 2011-06-23 MX MX2012014774A patent/MX2012014774A/es not_active Application Discontinuation
- 2011-06-23 WO PCT/DK2011/000067 patent/WO2011160630A2/en not_active Ceased
- 2011-06-23 PH PH1/2012/502461A patent/PH12012502461A1/en unknown
- 2011-06-23 NZ NZ604033A patent/NZ604033A/en not_active IP Right Cessation
- 2011-06-23 JP JP2013515697A patent/JP5937582B2/ja not_active Expired - Fee Related
- 2011-06-23 PE PE2012002434A patent/PE20130326A1/es not_active Application Discontinuation
- 2011-06-23 BR BR112012033227A patent/BR112012033227A2/pt not_active IP Right Cessation
- 2011-06-23 SG SG2012090890A patent/SG186276A1/en unknown
- 2011-06-23 AP AP2013006669A patent/AP3286A/xx active
- 2011-06-23 KR KR1020137000529A patent/KR20130086339A/ko not_active Withdrawn
- 2011-06-23 EA EA201291233A patent/EA201291233A1/ru unknown
- 2011-06-23 AU AU2011269427A patent/AU2011269427A1/en not_active Abandoned
- 2011-06-23 CN CN2011800305150A patent/CN103038250A/zh active Pending
2012
- 2012-11-30 TN TNP2012000567A patent/TN2012000567A1/en unknown
- 2012-12-20 EC ECSP12012351 patent/ECSP12012351A/es unknown
- 2012-12-21 CL CL2012003643A patent/CL2012003643A1/es unknown
- 2012-12-21 CO CO12232550A patent/CO6660484A2/es unknown
2016
- 2016-06-27 US US15/194,025 patent/US20160304576A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG186276A1 (en)	2013-01-30
AP3286A (en)	2015-05-31
AU2011269427A1 (en)	2012-12-20
AR081975A1 (es)	2012-10-31
US20160304576A1 (en)	2016-10-20
CA2802889A1 (en)	2011-12-29
PH12012502461A1 (en)	2013-02-18
AP2013006669A0 (en)	2013-01-31
UY33462A (es)	2012-01-31
US9403894B2 (en)	2016-08-02
ECSP12012351A (es)	2013-01-31
EA201291233A1 (ru)	2013-07-30
WO2011160630A2 (en)	2011-12-29
JP2013534919A (ja)	2013-09-09
CN103038250A (zh)	2013-04-10
TW201202265A (en)	2012-01-16
MX2012014774A (es)	2013-01-29
TN2012000567A1 (en)	2014-04-01
KR20130086339A (ko)	2013-08-01
JP5937582B2 (ja)	2016-06-22
US20130157935A1 (en)	2013-06-20
PE20130326A1 (es)	2013-03-17
EP2585481A2 (en)	2013-05-01
WO2011160630A3 (en)	2012-02-16
NZ604033A (en)	2014-12-24
BR112012033227A2 (pt)	2017-06-20
CO6660484A2 (es)	2013-04-30
EP2585481B1 (en)	2015-08-19

Publication	Publication Date	Title
CL2012003643A1 (es)	2013-08-02	Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2011001299A1 (es)	2012-01-13	Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2011002877A1 (es)	2012-05-25	Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2012003415A1 (es)	2013-08-09	Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015001207A1 (es)	2015-07-03	Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
CL2014000801A1 (es)	2014-09-12	Variante de factor 21 de crecimiento de fibroblasto humano (fgf21); composicion farmaceutica que lo comprende; y su uso para tratar diabetes tipo 2, obesidad, dislipidemia, sindrome metabolico o cualquier combinacion de los mismos.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
BR112014031262A2 (pt)	2017-06-27	composições biocatalisadoras inovadoras e processos para uso.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
GT201400147A (es)	2015-04-06	Pirimidinas y triazinas fusionadas sustituidas y su uso
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CO6440531A2 (es)	2012-05-15	2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2008000793A1 (es)	2008-05-30	Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
CL2014002348A1 (es)	2015-01-23	Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2014003339A1 (es)	2015-04-10	Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor.
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015001202A1 (es)	2015-07-03	Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2013001324A1 (es)	2014-05-16	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.